Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations, capital structure, and governance. This page brings together those SEC filings and pairs them with AI-powered tools to help readers interpret the information more efficiently.
For Amneal, current reports on Form 8-K are a key source of timely disclosures. Recent 8-K filings describe quarterly financial results, including net revenue trends across the Affordable Medicines, Specialty, and AvKARE segments, as well as updates to full-year guidance. Other 8-Ks outline significant financing transactions, such as new seven-year term B loans, senior secured notes due 2032, and amendments to the company’s revolving credit agreement, along with details on collateral, covenants, and maturity profiles.
Filings also cover governance and stockholder matters. For example, Amneal has reported preliminary financial results, changes to board composition when designation rights shifted under a stockholders agreement, and the board’s decision to hold Say-on-Pay advisory votes on an annual basis following stockholder preferences expressed at an annual meeting.
On this page, users can access Amneal’s Forms 8-K and, through links to its broader filing history, locate annual reports on Form 10-K and quarterly reports on Form 10-Q. These longer-form filings typically include segment discussions for Affordable Medicines, Specialty, and AvKARE, risk factor summaries, and explanations of non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS referenced in earnings releases.
AI features on the platform provide summaries and highlights of lengthy filings, helping readers identify key topics such as segment performance, debt structure, covenant changes, and governance decisions without reading every line. Users interested in AMRX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures, and better understand how regulatory documents reflect Amneal’s evolving business and capital structure.
Amneal Pharmaceuticals is moving ahead with a nationwide agreement to settle a substantial majority of opioids-related claims brought by states and local subdivisions. The settlement becomes effective on January 29, 2026.
Under the agreement, Amneal will pay participating states and subdivisions $88.5 million in cash and provide up to $177.4 million in naloxone nasal spray, valued at $125 per twin pack, to help treat opioid overdoses. Instead of product, settling parties may elect to receive 25% of the naloxone value, up to $44.4 million in additional cash during the final four years of the ten‑year payment term, which would bring the total cash commitment up to $132.9 million.
Amneal Pharmaceuticals plans to tell investors it expects to meet or exceed its previously issued 2025 full-year financial guidance. The company continues to target net revenue of $3.0 billion to $3.1 billion, adjusted EBITDA of $675 million to $685 million, adjusted diluted EPS of $0.75 to $0.80, operating cash flow of $300 million to $330 million, and capital expenditures of about $100 million net of a $20 million alliance contribution.
Amneal also estimates its net leverage as of December 31, 2025 to be about 3.6x, improved from 3.9x a year earlier. The outlook relies on management’s assumptions about prescription trends, pricing, product launches, restructuring impacts and strategy execution, and uses several non-GAAP measures such as adjusted EBITDA, adjusted diluted EPS and net leverage, which exclude items like acquisition and restructuring costs, legal charges and certain non-cash expenses.
Amneal Pharmaceuticals, Inc. filed a Form 4 showing a share sale by one of its directors. On 11/17/2025, the reporting person sold 50,000 shares of Amneal Class A common stock in an open-market transaction coded "S" for sale. The weighted average sale price was $11.72 per share, with individual trades executed between $11.70 and $11.75 per share.
After this transaction, the reporting person beneficially owns 291,029 shares of Amneal Class A common stock in direct ownership form. The filing notes that full details of the individual trade prices within the reported range are available upon request.
Amneal Pharmaceuticals, Inc. (AMRX) reported insider activity by its Executive Vice President. On November 12, 2025, the officer exercised stock options for 36,331 and 95,525 shares at an exercise price of $2.75 per share and sold 131,856 Class A shares at a $11.92 weighted average price.
The sale occurred across multiple trades between $11.85 and $12.02 per share. Following these transactions, the reporting person directly beneficially owned 146,403 shares. The reported option grants (fully vested) show 0 derivative securities remaining after exercise, with prior expirations listed as May 7, 2028 and March 1, 2029.
Amneal Pharmaceuticals (AMRX) reported Q3 2025 results. Net revenue was $784.5 million, up from $702.5 million a year ago. Operating income was $70.3 million versus $88.8 million. Net income attributable to Amneal was $2.4 million, or $0.01 per diluted share.
Performance by segment in Q3: Affordable Medicines $460.7 million, Specialty $125.2 million, and AvKARE $198.5 million. Year to date, net revenue reached $2.20 billion and operating income was $282.1 million, with diluted EPS of $0.11.
Results reflect a $31.4 million loss on refinancing, a $22.8 million intangible asset impairment tied to an FDA complete response letter dated July 22, 2025, and a tax benefit from the One Big Beautiful Bill Act that reduced current income tax liabilities by $23.5 million in Q3. Cash from operating activities for the first nine months was $209.7 million, with cash and cash equivalents of $201.2 million at September 30, 2025. Long‑term debt, net, was $2.57 billion.
Amneal Pharmaceuticals (AMRX) furnished an 8‑K announcing it issued a press release for its third quarter ended September 30, 2025. The information was provided under Item 2.02 and Item 7.01 and is being treated as furnished, not filed.
Amneal will host a conference call and live webcast at 8:30 a.m. Eastern Time on October 30, 2025. Access the webcast via the Investor Relations site at https://investors.amneal.com or join by phone at (833) 470‑1428 (U.S.) with access code 272787. A replay will be posted after the call, with international dial-in options available at the provided NetRoadshow link.
Amneal Pharmaceuticals, Inc. reporting person Chintu Patel amended a Schedule 13D to disclose ownership of 25,910,032 shares of Class A common stock, representing 8.2% of the outstanding Class A shares based on 314,079,309 shares outstanding. On October 3, 2025 Mr. Patel caused a trust he controls to contribute 13,257,287 shares to Shivkan Holdings X, LLC, the Trust's wholly owned LLC. Shivkan then entered a margin loan with Citibank, pledging those 13,257,287 shares as collateral under a Pledge and Security Agreement; the loan matures on April 5, 2027. The filing notes Citibank may foreclose and dispose of the pledged shares upon customary events, and an Issuer Letter Agreement was entered to facilitate Citibank's rights.
Amneal Pharmaceuticals, Inc. Schedule 13D/A shows that Dipan Patel beneficially owns 23,828,992 shares of Class A common stock, representing 7.6% of the 314,079,309 shares outstanding used for the calculation. The filing states these shares are held of record by trusts controlled by the reporting person and that Patel has sole voting and dispositive power over the shares.
The amendment adds loan documentation: a trust controlled by Patel pledged 3,050,000 Class A shares as collateral under a promissory note and related agreements with Enterprise Bank & Trust. The loan matures on 11/05/2026, and customary foreclosure rights exist for the bank if events of default occur.
Amneal Pharmaceuticals director John Kiely reported a sale of Class A common stock on 08/27/2025. The Form 4 shows 32,000 shares were sold at a weighted-average price of $9.23 per share (prices ranged $9.20–$9.25). After the sale, the reporting person beneficially owned 225,433 shares, held directly. The filing was signed by an attorney-in-fact on 08/28/2025. The Form 4 discloses the transaction details and the footnote states the seller will provide a breakdown of shares sold at each price upon request.
Amneal Pharmaceuticals (AMRX) filed a Form 144 to notify a proposed sale of 32,000 Class A shares through Merrill Lynch (157 Church St, New Haven, CT) with an approximate sale date of 08/27/2025. The filing reports an aggregate market value of $293,810 for the shares and shows 314,079,309 shares outstanding for the class. The shares were acquired on 05/10/2024 as equity compensation from Amneal Pharmaceuticals, with payment recorded on the same date. The filer reports no sales in the past three months and provides the standard certification that no undisclosed material adverse information is known.